Search
First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition
- OPACC
- Aug 30, 2024
- 1 min read
Scientists and clinicians at St. Jude Children’s Research Hospital identified the genetic vulnerability BARD1 in a patient with pediatric neuroblastoma, successfully treating the disease with targeted therapy.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
コメント